Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07365462 | Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia | PHASE2 | RECRUITING | 100 | — | — | Feb 6, 2026 | Mar 1, 2027 | May 19, 2026 | 17 | United States |
| Arm | Type | Description |
|---|---|---|
| NBI-1065890 | EXPERIMENTAL | Participants will receive NBI-1065890. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo matching NBI-1065890. |
| Name | Type | Description |
|---|---|---|
| NBI-1065890 | DRUG | Oral administration |
| Placebo | DRUG | Oral administration |
Key Inclusion Criteria: * Medically confirmed diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, or major depressive disorder (MDD) as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) for at least 3 months prior to screening. * Medical...